Treatment of refractory uveitic macular edema: Results of a first and second implant of long-acting intravitreal dexamethasone by Zola, Marta et al.
© 2017 Zola et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php  
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Clinical Ophthalmology 2017:11 1949–1956
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1949
O r i g i n a l  r e s e a r C h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/OPTH.S141153
Treatment of refractory uveitic macular edema: 
results of a first and second implant of long-acting 
intravitreal dexamethasone
Marta Zola
Cristina Briamonte
Umberto lorenzi
Federica Machetta
Federico M grignolo
antonio M Fea
Ophthalmic eye hospital, Department 
of surgical sciences, University of 
Turin, italy
Purpose: The purpose of this study was to report the functional and anatomical outcomes of a 
prospective study resulting from repeated dexamethasone intravitreal implants in patients with 
uveitic refractory macular edema.
Methods: Twelve eyes of 9 patients with intermediate and posterior noninfectious inflammatory 
uveitis complicated with refractory macular edema were regularly reviewed after a dexametha-
sone intravitreal implant. Patients were examined at baseline, 30, 90, 135, and 180 days with 
best-corrected visual acuity (BCVA), complete slit-lamp examination, intraocular pressure (IOP), 
optical coherence tomography, and fluorescein angiography. After 6 months of follow-up, eyes 
were reassessed to receive a second implant. 
Results: BCVA significantly improved when comparing the baseline values after the first and 
second implant (16.2 and 25.8 letters, respectively, 9.6 letters improvements, p,0.05). BCVA 
was better after the second implant compared to the first one throughout the follow-up, but 
without statistical significance. Mean central macular thickness (CMT) was 446.3±129.9 μm 
at baseline and was significantly reduced until day 135 (p,0.05). CMT reductions after the 
second injection showed a similar pattern, though differences were not statistically significant. 
Cataract progression was observed in 4 of 8 phakic eyes (50%) after the first implant, and in 
2 of 3 phakic eyes following the second implant, with 1 eye requiring cataract surgery. One eye 
developed an IOP .30 mmHg 30 days after the second implant, treated topically.
Conclusion: Repeated dexamethasone intravitreal implants in uveitic patients with refractory 
macular edema can be used effectively in a clinical setting with an acceptable safety profile.
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Introduction
Uveitis is a group of inflammatory diseases of the eye accounting for 10%–15% of 
legally blind people in the Western world.1–3 Noninfectious uveitis is the most com-
mon cause of uveitis. The clinical presentation is often a chronic and/or recurrent 
inflammation, leading to the breakdown of the inner and outer blood–retinal barrier, 
to increased vessels permeability, swelling of the central retina, and cystoid macular 
edema (CME). Several factors are implicated, including increased levels of vascular 
endothelial growth factor, inflammatory mediators (prostaglandins, interleukin-6), as 
well as a reduction of the endothelial tight junctions.4–7 Corticosteroids were the main-
stay in the treatment of uveitis, with considerable advances in the immunosuppressive 
therapy established in recent years.8,9 Steroids present important systemic and ocular 
side effects, the latter being increased intraocular pressure (IOP) with a varying range 
of 20.8%–52% and accelerated cataract formation in 29% of patients.10–15 The most 
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effective route of administration of steroids is a matter of 
debate.16,17,30 The Ozurdex® implant (Allergan, Inc, Irvine, CA, 
USA) injected into the vitreous chamber through a 22-gauge 
applicator has proved to be effective in treating macular 
edema from branch retinal vein occlusion/central retinal vein 
occlusion, as well as uveitis and other etiologies.18–22 The 
implant is a biodegradable copolymer composed of polylactic 
acid and polyglycolic acid that erodes into carbon dioxide and 
water, while dexamethasone is released into the eye.23,24
The purpose of this case series was to report our experi-
ence in a real-life setting of $1 dexamethasone intravitreal 
implants in patients affected by noninfectious intermediate 
uveitis, posterior uveitis, or panuveitis whose CME was 
refractory to other steroid therapies.
Methods
study design
This is a prospective, single center, interventional study. 
All patients signed an informed written consent form before 
initiation of the procedures performed as per standard of care 
according to the Italian Ophthalmic Society guidelines. The 
study was approved by the local Ethic Committee (Comitato 
Etico A.O.U Città della Salute e della Scienza – A.O. Ordine 
Mauriziano – A.S.L Città di Torino, protocol no 0033070).
study population
Patients of at least 18 years of age with a diagnosis of inter-
mediate or posterior noninfectious inflammatory uveitis or 
panuveitis with persistent macular edema lasting for $90 days 
refractory to oral or peribulbar steroid treatment were offered 
long-acting dexamethasone intravitreal implant. Patients had 
steroid systemic treatment that had to be stable for $3 months 
at the time of the injection. After the dexamethasone intra-
vitreal injection, no systemic treatment was added. All 
eyes received topical nonsteroidal anti-inflammatory drugs 
3 times a day for 1 month following the injection.
Key exclusion criteria were moderate or severe glau-
coma not controlled by medical therapy, steroid responder 
patients (defined as IOP $30 mmHg or rise of $15 mmHg 
after steroid administration), poorly controlled hypertension 
(defined as systolic pressure .160 mmHg and diastolic 
pressure .90 mmHg), and poorly controlled diabetes (with 
HbA1c .13%).
study treatment
From November 2011 to January 2014, 12 eyes of 9 patients 
were included in the study. The dexamethasone intravitreal 
implant was inserted into the vitreous cavity through the 
pars plana using a single-use 22-gauge applicator by an 
experienced ophthalmologist (AMF). Prior to each treatment, 
the study eye was anesthetized with topical anesthetics and 
prepared according to standard guidelines of the Italian 
Ophthalmic Society for intravitreal injection of the long-
acting dexamethasone implant. All patients were treated 
with a topical ophthalmic antibiotic 4 times a day starting 
3 days prior to the day of their study procedure (day 0) and 
continuing for 5 days after the procedure.
Outcome measures and follow-up
Patients were evaluated at baseline, 7, 30, 90, 135, and 180 days 
after the study treatment. The primary outcome at 6 months 
was improvement of best-corrected visual acuity (BCVA) 
measured using the standardized Early Treatment Diabetic 
Retinopathy Study protocol. Secondary outcomes were 
reduction of central macular thickness (CMT) and improve-
ment of ocular inflammation. Complete slit-lamp biomicros-
copy was performed in order to detect nuclear, cortical, or 
posterior subcapsular lens opacities and signs of inflamma-
tion in the anterior chamber (Tyndall effect, cells, flare). IOP 
was measured with a Goldmann applanation tonometer using 
a cutoff of $25 mmHg or a rise of $20% compared to the 
patient’s baseline IOP to treat ocular hypertension. Posterior 
ocular inflammation was evaluated through indirect fundus 
examination for vitreous haze evaluation and examination 
of the posterior pole of the retina. Fluorangiography (HRA1; 
Heidelberg, Germany) was also performed with intravenous 
fluorescein and indocyanine green taking images of both the 
posterior pole and retinal periphery during early, mid, and 
late phases. Measurements of CMT were carried out using 
optical coherence tomography (OCT; SD-OCT RTV100; 
Optovue Inc, Fremont, CA, USA).
The primary outcome of BCVA improvement was evalu-
ated using a cutoff of a 15-letter improvement (3 lines on 
standard visual acuity chart) and a second 10-letter improve-
ment cutoff (2 lines on standard visual acuity chart). CMT 
thickness reduction was considered significant when it 
reduced .20% compared to the initial value.
Eyes were reassessed after 6 months of follow-up to 
receive a second implant. Eyes with a BCVA improvement 
of $10 letters and/or a decrease in CMT of $20% compared 
to baseline were considered to be responding to the treatment. 
Eyes with a BCVA improvement of ,10 letters and those 
with a CMT reduction ,20% at OCT were considered as 
non-responding to the treatment.
lens status
The Lens Opacities Classification System (LOCS) III 
grading system was used to assess the severity of cataract. 
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The threshold for referring a patient for cataract surgery was 
a progression of lens opacity according to the LOCS system 
associated with reduction of BCVA.
Data analysis and statistical methods
Mean values of BCVA, CMT, and IOP were recorded at 
each visit and compared with baseline values using Student’s 
t-test for paired samples. An α level of 0.05 was considered 
statistically significant. Baseline digital photos were taken 
to evaluate the reduction of ocular inflammation throughout 
the follow-up and were compared on a clinical basis.
Results
Patient demographics and baseline characteristics are listed 
in Table 1.
Mean age was 60.8 years (range 23–78 years), two-
third of the patients were male, and the vast majority (8 of 
9 patients, 88.9%) were Caucasians. Seven out of 12 eyes 
(58.3%) were phakic, 4 (33.3%) were pseudophakic, and 
1 eye (8.7%) was aphakic. Epiretinal membranes (ERMs) 
were present at baseline in 4 eyes, 4 developed it during 
the follow-up, and in 4 eyes no membranes were observed 
throughout the whole period. None of the ERMs required 
surgical intervention. During the visit at day 180, 5 eyes 
of 5 patients were considered suitable to be reinjected: all 
of them presented an improvement of both central retinal 
thickness (CRT) and BCVA. The mean reinjection time 
was 8.8 months (range 7–10) (Table S1). Seven eyes of 
4 patients did not show a significant improvement in BCVA 
or a reduction in CMT and were not reinjected. Three of 
these had stable visual acuity at day 180, whereas in 3 other 
eyes no significant improvement in BCVA was detected 
throughout the follow-up. Migration of the implant into the 
anterior chamber happened in 1 aphakic eye, and thus was 
not considered suitable for repeated injections.
Visual acuity
First implant
Mean BCVA changes after 1 dexamethasone intravitreal 
implant in the 12 eyes considered in this study are shown 
in Figure 1. Pre-implant mean visual acuity was 20.3 letters 
(±15.9). It showed significant improvement at all follow-up 
visits (p,0.05), with a gain of 12 letters (32.3±18.1) at 
day 30, 11.9 letters (32.25±18.9) at day 90, 10.1 letters 
(30.4±18.7) at day 135, and 8 letters (28.3±17.9) at day 180. 
Fifty percent of the eyes (6 out of 12) had a 15-letter improve-
ment at day 30 and 90, and 25% (4 out of 12) at day 135 
and 180. Fifty percent of the patients obtained a 10-letter 
Table 1 Patient demographics and baseline characteristics
Patient Age Sex Diagnosis Therapy Basal 
BCVA
Responders Lens ERM at 
baseline
1 55 M re: idiopatic recurrent 
panuveitis
Prednisone 25 mg/day
Dexamethasone 1 drop/day
Methotrexate 2.5 mg/week
45 no Phakic no
2 75 M re: idiopatic 
granulomatous panuveitis
Dexamethasone 2 drops/day
Prednisone 2.5 mg/day
25 Yes Pseudophakic Yes
3 74 F le: recurrent uveitis 
with CMO
Bromfenac 2 drops/day
Dexamethasone 1 drop BiD
Prednisone 5 mg/day
1 no surgical 
aphakia
no
4 46 M re: intermediate uveitis Prednisone 25 mg/day
hydroxychloroquine 200 mg/day
30 Yes Phakic no
no
5 60 F Be: intermediate uveitis Prednisone 5 mg/day
Methotrexate 10 mg/week
Dexamethasone 4 drops/day
subconjunctival triamcinolone 
acetonide 40 mg
47
45
no
no
Phakic
Phakic
Yes
Yes
6 23 M re: intermediate uveitis 
in CMO
LE: vasculitis in Behcet’s-
like disease
Prednisone 10 mg/day
Cyclosporine a 200 mg/day
azathioprine 50 mg/day
Brinzolamide/timolol 2 drops/day
1
30
Yes Phakic
Phakic
no
no
7 70 M re: multifocal choroiditis netildex 4 drops/day 5 no Phakic Yes
8 78 F Be: panuveitis Prednisone 5 mg/day
Dexamethasone 3 drops/day
20
5
Yes
Yes
Pseudophakic
Pseudophakic
Yes
Yes
9 67 M re: recurrent uveitis  
in sarcoidosis
Prednisone 5 mg/day
Cyclosporine 150 mg/day
MTX 10.5 mg/week
10 Yes Phakic no
Abbreviations: RE, right eye; LE, left eye; BE, both eyes; M, male; F, female; ERM, epiretinal membrane; BID, twice a day; CMO, cystoid macular oedema; BCVA, best-
corrected visual acuity.
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improvement at days 30, 90, and 135. This was maintained 
in 33% of the eyes at day 180. BCVA improvement main-
tained its statistical significance when analyzing only the 
worst eye of patients who received treatment in both eyes 
(Table S2).
second implant
Considering the reinjected eyes, mean visual acuity showed a 
significant increase of 10.6 letters (p,0.05) after the second 
implant at day 30 (36.4±10.9 letters compared to 26±13.6 
letters at baseline). Although BCVA increased during the 
entire period with a gain of 9.2 letters (35±14.5 letters) 
at 90 days, 7.2 letters (33±14.8 letters) at 135 days, and 
4.2 letters (30±14.5 letters) at 180 days, the difference with 
baseline values was not statistically significant (p.0.05) 
(Figure 2).
CMT
First implant
Mean CMT was 446.3±129.9 μm at baseline and was sig-
nificantly reduced throughout the 135th day of follow-up 
visit (p,0.05) (Table 2).
In all, 66.7% (8 out of 12) of the patients presented a CMT 
reduction $20% compared to mean baseline values until 
day 135. This percentage reduced to 33% at the 6 months 
follow-up visit. When analyzing only the worst eyes of those 
patients who received treatment in both eyes, the CMT was 
significantly reduced until day 135 (p,0.05) (Table S2).
second implant
CMT at baseline was 493.2±134.6 μm. At day 30, CMT 
was reduced to 360.8±134.6 μm, to 371.6±102.3 μm at 
90 days, to 445.8±157.7 μm at 135 days, to 462.8±187.5 μm 
at 180 days (p.0.05) (Table 3). CMT reductions after the 
second injection showed a similar pattern when compared to 
the first injection, though differences between the 2 groups 
were not statistically significant.
iOP
Following the first implant, mean IOP at baseline was 
11.91±3.57 mmHg. It rose to 13.75±4.24 mmHg 30 days 
after the procedure, to 14.33±5.10 mmHg at day 90, to 
13±3.41 mmHg at day 135, and to 13.91±2.06 mmHg at 
6 months follow-up. These variations never appeared to be 
statistically significant (p.0.05). An IOP $25 mmHg was 
not observed during the first implant.
After the second implant, IOP was higher at 30 days 
(17±7.77 mmHg) compared to pre-implant values (14.6±5.4 
mmHg). This was due to a single eye which developed an 
IOP of 30 mmHg at day 30 and was successfully treated with 
topical therapy (brinzolamide 10 mg/mL + timolol 5 mg/mL) 
until the following visit at day 90.
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Figure 1 Changes in BCVa following one dexamethasone intravitreal implant in 
12 eyes affected by noninfectious inflammatory uveitis.
Note: *Significant difference between mean values at baseline and follow-up visits.
Abbreviations: BCVA, best-corrected visual acuity; ETDRS, Early Treatment 
Diabetic retinopathy study.
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Figure 2 evolution of BCVa following the second dexamethasone intravitreal 
implant in 5 eyes.
Note: *Significant difference between mean baseline values and follow-up visits.
Abbreviations: BCVA, best-corrected visual acuity; ETDRS, Early Treatment 
Diabetic retinopathy study.
Table 2 Changes in mean CMT following one dexamethasone 
intravitreal implant, in 12 eyes diagnosed with noninfectious 
inflammatory uveitis
CMT (μm) First implant 
(mean ± SD) 
p-value
Baseline 446.3±129.9
30 days 320±97 ,0.05
90 days 310.2±43 ,0.05
135 days 313±45.7 ,0.05
180 days 395±145.3 0.09
Abbreviation: CMT, central macular thickness.
Table 3 Changes in mean CMT following a second dexamethasone 
intravitreal implant in 5 eyes diagnosed with noninfectious 
inflammatory uveitis
CMT (μm) Second implant 
(mean ± SD) 
p-value
Baseline 493.2±135
30 days 360±112 0.06
90 days 371.6±102.3 0.06
135 days 446±157.8 0.08
180 days 462.8±188 0.4
Abbreviation: CMT, central macular thickness.
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lens status
Cataract progression was observed in 4 of 8 phakic eyes 
(50%) after the first dexamethasone intravitreal implant, 
and in 2 of 3 phakic eyes following the second implant, 
with 1 eye requiring cataract surgery with posterior chamber 
intraocular lens implant.
anterior chamber migration
Migration into the anterior chamber of the device was 
observed 24 hours after the injection in the only aphakic 
patient. This complication was handled with pupil dila-
tion and postural maneuvres, enabling repositioning of the 
implant in the vitreous chamber (Figure S1).
repeat injections of dexamethasone
Mean BCVA values of the 5 patients who underwent the 
first and the second implant are plotted in Figure 3. For 
those patients who received 2 dexamethasone intravitreal 
implants, mean values of BCVA and CMT were compared 
for the baseline and for each subsequent visit. Mean visual 
acuity at baseline was better before the second implant 
compared to initial visual acuity prior to the first implant. 
There was a 9.6-letter improvement (16.2 letters before 
first implant and 25.8 letters before second implant); this 
difference was statistically significant (p,0.05). All the 
following visits showed a greater BCVA after the second 
device implant compared to the first one (36.4 vs 33.6 letters 
at 30 days, 35 vs 32.2 letters at 90 days, 33.4 vs 30 letters at 
135 days, 31.4 vs 28 letters at 180 days), but none were statis-
tically significant. CMT of the first implant was 504.4 μm at 
baseline, 373 μm at 30 days, 319.4 μm at 90 days, 348.6 μm 
at 135 days, and 485 μm at 180 days, whereas during the 
second treatment it reached 493.2, 360.8, 371.6, 445.8, 
and 462.8 μm, respectively. These differences were not 
statistically significant.
Vitreoretinal interface
Six eyes out of 12 (50%) demonstrated abnormalities of the 
vitreo-macular interface, ranging from subtle thickening 
without traction (5 eyes, 41%) to ERMs. We did not notice 
a progression of the ERM during follow-up. In all these 
cases, after the implant the membranes followed the shape of 
the retina suggesting that the tractional role was minimal 
(Figures S2–S4). 
Conclusion
Blindness is attributed to uveitis in 10%–15% of cases in 
the developed world.1 One of the most common complica-
tions is CME, which may be particularly difficult to treat. 
Its chronicity accounts for severe visual loss, occurring in 
25%–50% of patients.2–4
In this study, we examined the effect of repeated intra-
vitreal injections of 0.7 mg long-acting dexamethasone in 
eyes with recalcitrant macular edema secondary to nonin-
fectious inflammatory uveitis in a clinical setting. All eyes 
had undergone at least one line of therapy, with oral steroids 
and/or immunosuppressive medications, without any effect 
on the macular edema.
After the first implant, we found 1) a significant improve-
ment of BCVA through the entire 6 month follow-up period, 
2) a significant reduction of CMT until day 135, with a 
thickness increase observed at 180 days, 3) a safety profile 
consistent with the other studies, and 4) a case of anterior 
chamber dislocation in aphakic eye, successfully treated with 
postural maneuvres.
The HURON study22 examined the use of a single dexam-
ethasone implant in cases of chronic noninfectious uveitis, 
showing an improvement in BCVA and vitritis accompanied 
by a decrease in CRT. In the 77 eyes receiving 0.7 mg long-
acting dexamethasone, the mean visual acuity was 58 letters at 
baseline, with 46.2% of eyes achieving a $15-letter improve-
ment at 6 months (p,0.001). In an observational case series 
on repeat dexamethasone implants in noninfectious uveitis by 
Tomkins-Netzer et al,25 the mean baseline visual acuity was 
0.47 and 0.43 at 6 months. Zarranz-Ventura et al26 reported in 
another multicenter retrospective cohort study a visual acuity 
of 0.68 logMAR at baseline, significantly improving to 0.6 
logMAR at 6 months. In our cohort, pre-implant BCVA, with 
a mean value of 20.3 (±15.9) letters, significantly improved to 
28.3±17.9 letters (p,0.05) at 6 months, and 4 out of 12 eyes 
(25%) showed a 15-letter improvement at the same time 
point. These values seem to be more in line with retrospec-
tive studies,25,26 having patient inclusion criteria not as strict 
as those found in randomized trials.22 CRT was significantly 
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Figure 3 Best-corrected mean visual acuity after 1 dexamethasone intravitreal 
implant in 5 eyes of 5 patients who responded to treatment.
Notes: **The difference between mean baseline values showed statistical difference. 
First implant: straight line, second implant: dotted line.
Abbreviations: BCVA, best-corrected visual acuity; ETDRS, Early Treatment 
Diabetic retinopathy study.
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reduced initially, increasing subsequently at 6 months. 
A similar trend was noted by Nobre-Cardoso et al,27 where 
the relapse of macular edema occurred at 3 months after the 
first injection.
Following our re-treatment criteria, 6 eyes were not 
treated: 3 eyes because the patients responded to the first 
implant without a recrudescence of the disease at 180 days; 
and 3 other eyes because the reduction of CMT was not 
associated with an improvement of visual acuity during the 
follow-up. Repeated injections achieved a BCVA gain similar 
to the first implant throughout the entire period, a reduction 
in CMT that was stable during the follow-up, although not 
statistically significant. Comparing the follow-up visits of the 
first and second implant, we noticed that functional improve-
ment was similar, whereas the time trend of CMT differed. 
As the first treatment induced an initial CMT reduction 
followed by a relapse of macular edema, the second implant 
stabilized it at lower values during the whole follow-up. 
Other studies found a better functional and anatomical 
profile before the second implant in eyes receiving multiple 
injections.27,28
The risk of increased IOP is a well-known side effect 
after dexamethasone intravitreal implant,10,11,18 and in non-
steroid responders it can be effectively managed with topical 
therapy.22,25–27 In our cohort, 1 out of 12 eyes had an 
IOP .21 mmHg (8.3%) after the first injection and 1 out 
of 5 eyes had an IOP .25 mmHg (20%) after the second 
injection. Both were effectively treated with local IOP low-
ering medication. The rate of this complication was similar 
to that found by Tomkins-Netzer et al (7.9% after first 
implant, 17.4% after second implant), and lower compared 
with other studies.26,27 Cataract progression occurred in 4 
out of 8 phakic eyes after the first implant and in 2 out of 3 
phakic eyes after the second implant; in both cases, cataract 
surgery was required. The rates of cataract incidence vary 
by a considerable degree, with 50% of eyes developing 
cataract in the study published by Arcinue et al,29 to 4.9% 
in the HURON study,22 or 7% in the retrospective analysis 
of 47 eyes.27 We estimate that the cohort of phakic patients 
in this study is too scarce to be comparable to other studies. 
Anterior chamber migration of the device is an adverse event 
reported in the literature and one of the risks underlined in 
the Food and Drug Administration Safety Report for aphakic 
and (anterior chamber intraocular lens) AC-IOL eyes.31–34 
In our series, the anterior chamber displacement occurred 
in the only aphakic eye of our study and it was successfully 
managed with postural maneuvres. Evidence of complica-
tions in aphakic patients and AC-IOLs is stronger at present,35 
while this was not the case during the inclusion of patients 
in this study. Before the first injection, 8 of 12 eyes (66%) 
presented with an ERM, without metamorphopsia or trac-
tion. The implant proved effective in reducing the macular 
thickness even in the presence of ERM and determined 
a functional improvement. In a few cases reported in the 
literature, intravitreal dexamethasone implant in association 
with a vitreo-macular traction resulted in the formation of 
a macular hole or pseudohole.36,37 In our study, no macular 
hole presented over the 26 months study.
This paper had some limitations especially concerning the 
less number of patients and the absence of a control group to 
compare the results. Also, a longer follow-up with a higher 
reinjection frequency would allow to detect changes and side 
effects more accurately.
In conclusion, this single-arm interventional prospective 
study illustrates how dexamethasone intravitreal implant in 
uveitic patients with refractory macular edema can be used 
effectively in a clinical setting. It also shows that in patients 
with alterations of the vitro-macular interface, the implant 
can be effective in reducing the macular thickness before any 
surgical therapy is attempted. Patients with recurrent macular 
edema may benefit from a second implant although some 
of them can show an increase of IOP. Further randomized 
studies are needed to evaluate the role of dexamethasone 
multiple implant on cataract development.
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Supplementary materials
Table S1 Eyes receiving the first and second dexamethasone 
intravitreal implant, and the mean interval between injections
Study eyes and 
reinjection 
interval
First dexamethasone 
intravitreal implant
Second dexamethasone 
intravitreal implant
study eyes 12 5
reinjection interval, 
mean (range) 
months
0 8.8 (7–10)
Table S2 Changes in BCVa and CMT following one 
dexamethasone intravitreal implant in 9 eyes affected by 
noninfectious inflammatory uveitis, considering only the worst 
eye for patients receiving treatment in both eyes
Study 
visit
BCVA (ETDRS letters) 
mean ± SD (p-value)
CMT (μm)
(p-value)
Baseline 17.1±16.6 446.7±127
30 days 28±18.6
(0.01)
326.4±112
(0.005)
90 days 30±20
(0.004)
315.7±46.4
(0.006)
135 days 28±19.5
(0.008)
317.3±47
(0.009)
180 days 25±18.5
(0.02)
398±140
(0.23)
Abbreviations: BCVA, best-corrected visual acuity; CMT, central macular 
thickness; eTDrs, early Treatment Diabetic retinopathy study.
Figure S2 OCT image of an epiretinal membrane 30 days after intravitreal 
dexamethasone injection.
Abbreviation: OCT, optical coherence tomography.
Figure S3 OCT image of an epiretinal membrane 90 days after intravitreal 
dexamethasone injection.
Abbreviation: OCT, optical coherence tomography.
Figure S4 OCT image of an epiretinal membrane 180 days after intravitreal 
dexamethasone injection.
Abbreviation: OCT, optical coherence tomography.
Figure S1 Anterior chamber migration of the long-acting intravitreal dexamethasone 
implant with corneal edema in an aphakic patient. 
Notes: Postural maneuvres with previous pupil dilation allowed correct repositioning 
of the implant with full resolution of the corneal edema and restoration of the Va 
before the complication. (A) Migration of the dexamethasone intravitreal implant 
into the anterior chamber. (B) resolution of corneal edema after repositioning of 
the device into the vitreous chamber.
Abbreviation: Va, visual acuity.
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